1
|
Lázaro M, Varela S, Vazquez S, Villanueva M, Firvida J, Amenedo M, Afonso F, Senin C, Grande C. 9099 POSTER Biweekly Docetaxel-Cisplatin in Chemonaive Patients With Advanced Epidermoid Carcinoma of the Lung – a Phase II Study of Galician Lung Cancer Group. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72411-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Parra J, Martinez-Hernandez R, Barcelo M, Alı´as L, Also-Rallo E, Amenedo M, Calaf J, Baiget M, Bernal S, Gallano P, Tizzano E. P3.34 Ultrasound evaluation of nuchal translucency thickness and fetal movements in 98 pregnancies at risk for type I spinal muscular atrophy: relevance of the SMN2 copy number. Neuromuscul Disord 2010. [DOI: 10.1016/j.nmd.2010.07.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Casal J, Varela S, Anido U, Lázaro M, Fírvida JL, Vazquez-Estevez S, Villanueva M, Amenedo M, Caeiro M, Gomez A. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Vazquez S, Firvida J, Lázaro M, Barón FJ, Alonso-Jaudenes Curbera G, Amenedo M, Santomé L, Afonso FJ, Cardona JV, Casal J. A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7091] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Leon L, Vazquez S, Gracia J, Casal J, Lázaro M, Fírvida JL, Amenedo M, Santomé L, Cardona JV, Maciá S. A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Vazquez S, Leon L, Gracia J, Casal J, Lazaro M, Firvida J, Amenedo M, Santome L, Cardona J, Macia S. 9145 Bevacizumab (B), cisplatin and vinorelbine in chemo-naïve patients (P) with non squamous non small cell lung cancer (NSCLC): a galician lung cancer group phase II study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71858-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
7
|
Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U. Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19089 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel or cisplatin-gemcitabine. This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine. Methods: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression. Main eligibility criteria were: PS 0–1, no brain metastases, no history of hemoptysis, stable cardiac condition and no full dose anticoagulation. Primary endpoint was progression-free survival and secondary endpoints were RR, duration of response, OS, 1-year survival and safety profile of the combination. Results: 38 p have been enrolled in the study and data of 27 p have been included in this analysis. P characteristics were: male 66.7%; median age 57 years (range 41–74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1. Median number of cycles for B/cisplatin/vinorelbine was 4.0 (range 1–6) and median number of cycles for B maintenance was 2 (range 1–4). 17 p were evaluable for response according to RECIST criteria: PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months (range 0.7–11.1), median PFS was 4.6 months (95% CI: 2.6–6.6) and median OS has not been reached yet. Hematological toxicities were: 1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 3/4 non hematological toxicities were: vomiting (1p gr. 4), high blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 respiratory infection. No grade 3/4 hemoptysis were reported. Conclusions: This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC. Survival data will be updated. [Table: see text]
Collapse
Affiliation(s)
- L. Leon
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - S. Vázquez
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. M. Gracia
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Lázaro
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. L. Fírvida
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. Casal
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Amenedo
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - L. Santomé
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - R. Gallego
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - U. Anido
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| |
Collapse
|
8
|
Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ. Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7537 Background: Combination of platinum-based chemotherapy and radiotherapy is the standard treatment for p with unresectable stage III NSCLC, but considering the high rates of recurrence, it is necessary to improve these results. Erlotinib is an EGFR TKI that prolongs survival in p with recurrent and metastatic NSCLC. In this study, we aim to evaluate the role of erlotinib as maintenance therapy after a standard concurrent chemo-radiotherapy regimen in p with stage III NSCLC. Methods: P with unresectable stage IIIA/IIIB—without malignant effusions—NSCLC who had received a standard concurrent chemo-radiotherapy regimen and had no evidence of tumor progression were enrolled in this single arm, open-label phase II study and received erlotinib 150 mg/day po for 6 months. Main eligibility criteria were: PS 0–2, adequate bone marrow, hepatic and renal function and measurable disease by RECIST criteria. Primary endpoint was the percentage of p without evidence of disease progression after 6 months of erlotinib therapy and secondary endpoints were: PFS, OS, ORR and safety profile. Results: 49 p have been included in the study and data from 37 p are presented in this analysis. Baseline characteristics: median age 62 years (range 41–76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8. Most common previous chemo-radiotherapy regimen is cisplatin/docetaxel/RT (83.8%). 27 p were evaluable for tumor response: CR 22.2%; PR 12.8%; SD 55.6%; PD 7.4%. Median TTP was 7.3 months (95% CI 5.8–16.9) and median OS was 18.7 months (95% CI 11.8-NA). Most common adverse events related to erlotinib were rash 30.6% (3 p gr. 3) and diarrhea 16.7%. Conclusions: Erlotinib as maintenance therapy is an active and well tolerated treatment after concurrent chemo- radiotherapy in p with stage III NSCLC. In spite of the majority of patients are caucasian, males, smokers with squamous cell carcinoma, maintenance with single agent erlotinib reached a promising median OS of 18.7 months. Updated data will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Casal
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - S. Vázquez
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - L. León
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - M. Lázaro
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - J. L. Fírvida
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - M. Amenedo
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - G. Alonso
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - L. Santomé
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - F. J. Afonso
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| |
Collapse
|
9
|
Rubio JC, Vázquez S, Vázquez F, Amenedo M, Fírvida JL, Mel JR, Huidobro G, Alvarez E, Lázaro M, Alonso G, Fernández I. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 2009; 64:379-84. [PMID: 19139896 DOI: 10.1007/s00280-008-0884-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2008] [Revised: 11/18/2008] [Accepted: 11/21/2008] [Indexed: 11/27/2022]
Abstract
PURPOSE To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC). METHODS Chemonaive patients with measurable stage IIIB/IV NSCLC treated with gemcitabine and cisplatin (GC), or gemcitabine and docetaxel (GD), maximumsix cycles in a phase IIB trial. RESULTS A total of 108 patients were randomized. Response rates (GC vs. GD, respectively): complete 3.6/2.0%, Partial 30.9/38.0%. Median Overall Survival (OS): 8.9 months in both groups (P = 0.53); and median time to progression (TTP): 6.2/5.5 months respectively (P = 0.61). Toxicities included (GC vs. GD, respectively): grade 3-4 neutropenia 49.1/41.2%; grade 3 thrombocytopenia 30.9/3.9%; grade 3 anemia 14.5/3.9%. Non-haematological toxicity was similar, except for nausea and vomiting, (16.3/2%); renal toxicity (3.7/0%) and hepatic toxicity (5.6/12.7%). CONCLUSIONS With a higher overall response rate and lower toxicity, GD is a good first treatment option for advanced NSCLC.
Collapse
Affiliation(s)
- Joaquín Casal Rubio
- Department of Medical Oncology, Hospital do Meixoeiro, C/Meixoeiro, s/n, 36200, Vigo (Pontevedra), Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Huidobro G, Vázquez S, Lázaro M, Mel JR, Casal J, Castellanos J, Vidal Y, Fírvida JL, Amenedo M. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by bi-weekly D with concurrent thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Casal J, Vázquez S, Barón FJ, Fírvida JL, Amenedo M, Santomé L, Lázaro M, Alonso G. An open label non-randomized phase II trial of erlotinib following concurrent chemo-radiotherapy as maintenance therapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.18501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Fírvida JL, Esquerdo G, Amenedo M, Salgado M, LLorca C, Pérez E, Cervera Grau J, Ramos M. Biweekly docetaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Finally results of a phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Gaspar E, Firvida J, Amenedo M, Orts D, Salgado M, LLorca C, Ramos M, Perez E, Cervera J, Abal J. Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18147 Background: The activity and tolerability of third-generation agents led many investigators to evaluate doublet combinations in the hope that platinum analogues could be eliminated from the treatment of advanced NSCLC. To improve the therapeutic index of this combination, we performed a study with biweekly gemcitabine and docetaxel. Primary objective was determination of objective response rate (ORR). Secondary objectives were time to progression, tolerability and overall survival. Methods: Patients histologically confirmed of non-small cell lung cancer, aged ≥ 18, ECOG PS 0–2, measurable lesion according RECIST criteria, adequate bone marrow, renal and hepatic function were included. Prior chemotherapy was not allowed. Patients received treatment with a combination of Docetaxel 50 mg/m2 and gemcitabine 20,00 mg/m2 each 15 days for a maximum of 8 cycles. Results: Fifty patients were included between July 2005 and October 2006.Now we present the results of the first 32 patients: 88% were male, median age was 62.7 years old, 69% had ECOG 0–1 and 81% of patients had stage IV. Histology was squamous cell carcinoma (53%) adenocarcinoma (31%) and large cell carcinoma (16%). A total 221 cycles were administrated . Over 30 patients evaluable for response, none achieved CR, 11 PR (36%), 7 SD (23%) and 12 PD, with an overall response rate of 36%. Median follow up of patients is 16 months, with a median overall survival of 9 months. Grade 3–4 toxicity per patient was: neutropenia (6%).Grade 1–2 toxicity per patient asthenia (75%), and nauseas (30%). Conclusions: These results suggest that biweekly schedule of gemcitabine / docetaxel is a safe and active regimen in first line advanced NSCLC patients.Updated results will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Gaspar
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - J. Firvida
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - M. Amenedo
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - D. Orts
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - M. Salgado
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - C. LLorca
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - M. Ramos
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - E. Perez
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - J. Cervera
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| | - J. Abal
- Elda Hospital, Elda, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain
| |
Collapse
|
14
|
Fírvida JL, Esquerdo G, Amenedo M, Salgado M, Llorca C, González A, Pérez E, Cervera JM, Ramos M. Biweekly docetaxel and carboplatin as first line chemotherapy in advanced non small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17016 Background: Platinum therapy has been the backbone treatment in NSCLC. The concomitant use of platinum derivatives and taxanes has shown high antitumoral activity with moderate toxicity. To improve the therapeutic index of this combination, we performed a study with biweekly carboplatin and docetaxel. Primary objective was determination of objective response rate (ORR). Secondary objectives were time to progression, tolerability and overall survival. Methods: Patients histologically confirmed of non-small cell lung cancer, aged ≥ 18, ECOG PS 0–2, measurable lesion according RECIST criteria, adequate bone marrow, renal and hepatic function were included. Prior chemotherapy was not allowed. Patients received treatment with a combination of Docetaxel 50 mg/m2 and Carboplatin AUC-4 each 15 days for a maximum of 8 cycles. Results: Fifty patients were included between March 2004 and July 2005, 84% were male, median age was 63 years old (range 48–77), 78% had ECOG PS 0–1 and 64% of patients had stage IV. Histology was squamous cell carcinoma (54%) adenocarcinoma (36%) and large cell carcinoma (10%). A total 316 cycles were administrated (median 7, Range 1–12). Over 46 evaluable patients for response, one achieved CR, 13 PR, 21 SD and 11 PD, with an overall response rate of 30.5% (95% CI: 17.2–43.8). Median follow up of patients is 8.3 months, with a median TTP of 6.3 months and median overall survival of 11.1 months. Grade 3–4 toxicity per patient was: neutropenia (22.0%), asthenia (16.0%), anaemia (10.0%), thrombocytopenia (2%), mucositis (2%) and nauseas (2%). Conclusions: These results suggest that biweekly schedule of carboplatin / docetaxel is a safe and active regimen in first line advanced NSCLC patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. L. Fírvida
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - G. Esquerdo
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Amenedo
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Salgado
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - C. Llorca
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - A. González
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - E. Pérez
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - J. M. Cervera
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Ramos
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| |
Collapse
|
15
|
Vázquez S, Casal J, Vázquez F, Amenedo M, Fírvida J, Mel J, Huidobro G, Lázaro M, Alonso G, Constela M. P-589 Gemcitabineldocetaxel (GD) vs gemcitabinelcisplatin (GC) instage IIIB/IV advanced non-small cell lung cancer (NSCLC): Grupo gallego de cancer de pulmon (GGCP). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81082-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Casal J, Lázaro M, Vázquez S, Fírvida J, Santomé L, León L, Amenedo M, López C, Caeiro M, Huidobro G. P-199 Carboplatin (C), paclitaxel (P) and gemcitabine (G) inductiontherapy followed by thoracic conformal radiation therapy (TCRT) with or without concurrent CP in stage IIIA/B non-small cell lung cancer (NSCLC). A Galician Lung Cancer Group (GLCG) study. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80693-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Vázquez S, Villanueva M, Amenedo M, Firvida J, Lázaro M, Del Río L, Huidobro G, Mel J, Ramos M, Grande C. P-588 Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB+ IV) non-small-cell lung cancer (NSCLC). A phase II study of the Galician Lung Cancer Group. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81081-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, Lázaro M, Del Río L, Villanueva MJ, Álvarez E, Ramos M, Casal J. Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB+IV) non-small-cell lung cancer (NSCLC). A phase II study of the Galician Lung Cancer Group. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Vázquez
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - G. Huidobro
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. Amenedo
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - J. L. Fírvida
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. Lázaro
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - L. Del Río
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. J. Villanueva
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - E. Álvarez
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. Ramos
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - J. Casal
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| |
Collapse
|
19
|
Ramos M, Casal J, Galán A, Almanza C, León L, Amenedo M, Gonzalez A, Huidobro G, Giner V. Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Ramos
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - J. Casal
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - A. Galán
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - C. Almanza
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - L. León
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - M. Amenedo
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - A. Gonzalez
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - G. Huidobro
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| | - V. Giner
- Ctr Oncologico de Galicia, A. Coruña, Spain; Hosp do Meixoeiro, Vigo, Spain; Hosp de Sagunto, Valencia, Spain; Clínica Povisa, Vigo, Spain; Hosp Clínico de Santiago, Santiago de Compostela, Spain
| |
Collapse
|
20
|
Casal JR, Lazaro MQ, Vazquez SE, Firvida JLP, Almanza CM, Garcia J, Amenedo M, Castellanos J, Quintero G, Grande C. Carboplatin (C), paclitaxel (P) and gemcitabine (G) induction therapy followed by thoracic conformal radiation therapy (TCRT) with or without concurrent CP in stage IIIA/B non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. R. Casal
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - M. Q. Lazaro
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - S. E. Vazquez
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - J. L. P. Firvida
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - C. M. Almanza
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - J. Garcia
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - M. Amenedo
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - J. Castellanos
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - G. Quintero
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| | - C. Grande
- Complejo Hospitalario Univ, Hospital Xeral Cies, Vigo, Spain; Complejo Xeral-Calde, Lugo, Spain; Hosp Cristal Piñor, Ourense, Spain; POVISA, Vigo, Spain; Complejo Univ, Santiago, Spain; Ctr Oncologico, A’Coruña, Spain
| |
Collapse
|
21
|
Amenedo M, Vázquez F, Lázaro M, Casal J, Mel JR, Antón LM, Fírvida JL, Grande C, Castellanos J, Balcells M. A phase II study of irinotecan (CPT-11) and carboplatin in patients with previously untreated small cell lung cancer (SCLC): Preliminary results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Amenedo
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - F. Vázquez
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - M. Lázaro
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. Casal
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. R. Mel
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - L. M. Antón
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. L. Fírvida
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - C. Grande
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. Castellanos
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - M. Balcells
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| |
Collapse
|
22
|
Parra J, Amenedo M, Muñiz-Díaz E, Ormo F, Simó M, Vega C, Fernández JG, Senosiain R, Moliner E, Guinovart G. A new successful therapy for fetal chylothorax by intrapleural injection of maternal blood. Ultrasound Obstet Gynecol 2003; 22:290-294. [PMID: 12942503 DOI: 10.1002/uog.208] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
We present two cases of fetal chylothorax and hydrops diagnosed at 20 weeks' gestation, both of which underwent successful intrauterine treatment. In Case 1, a transient, near total resolution began 2 weeks after an iatrogenic hemothorax following a second thoracocentesis performed at 24 + 6 weeks. Because of pleural fluid reaccumulation, a Cesarean section was performed at 36 weeks. The 3805-g female neonate was admitted to neonatal intensive care but was discharged 50 days later in a healthy condition. In Case 2, resolution occurred after a third thoracocentesis and a second pleural injection of maternal blood, performed at 26 weeks. A 2660-g female neonate was delivered vaginally at 38 weeks. The infant remained asymptomatic and was discharged aged 4 days. Our experience suggests a possible useful role of intrapleural blood injection for the treatment of fetal chylothorax.
Collapse
Affiliation(s)
- J Parra
- Department of Obstetrics and Gynecology, Hospital de Sant Pau, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
León L, Cueva-Banuelos JF, Huidobro G, Fírvida JL, Amenedo M, Lázaro M, Romero C, Estévez SV, Barón FJ, Grande C, García Mata J, González A, Castellanos J, Gómez A, Caeiro M, Rodríguez MR, Casal J. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group. Lung Cancer 2003; 40:215-20. [PMID: 12711124 DOI: 10.1016/s0169-5002(03)00030-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
PURPOSE To determine the effectiveness of a gemcitabine-cisplatin-vinorelbine combination in patients with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients (n=46) with stage III NSCLC and naive of therapy were recruited into the trial to receive gemcitabine (G, 1000 mg/m(2)) on days 1 and 8, cisplatin (C, 100 mg/m(2)) on day 1 and vinorelbine (V, 25 mg/m(2)) on days 1 and 8 every 21 days for three cycles. RESULTS Two patients achieved complete response (CR) and 23 partial response (PR), overall response 52%. Subsequent radical surgery included nine patients of whom four were non-resectable and five were resected and with 1 CR. Radiotherapy was administered to 31 patients, and two achieved CR. The median time to progression and overall survival were 37 and 50 weeks, respectively. Grade 3-4 neutropenia and thrombocytopenia occurred in 35% of cycles, with two toxic deaths. Severe non-haematological toxicity was uncommon. CONCLUSIONS This GCV combination is effective in patients with stage III NSCLC, and with an acceptable toxicity.
Collapse
Affiliation(s)
- Luis León
- Galician Lung Cancer Group, Pontevedra, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ramos M, González-Ageitos A, Amenedo M, González-Quintas A, Gamazo JL, Togores P, Losada G, Almanza C, Romero C, Gómez-Martín C. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 2003; 15:192-7. [PMID: 12797398 DOI: 10.1179/joc.2003.15.2.192] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
This phase II trial evaluated the efficacy and toxicity of weekly docetaxel as treatment of advanced metastatic breast cancer patients resistant to prior anthracycline chemotherapy. After the first 18 patients, the initial dose (40 mg/m2, 30-min i.v. infusion for 6 consecutive weeks, followed by 2-week rest) was reduced to 36 mg/m2 in the remaining 17 patients due to the incidence of toxicity (28% grade 3-4 asthenia). Overall response rate was 34% (95% CI, 19-50): two complete (6%) and ten partial responses (28%) were found. The median duration of response was 6.8 months, the median time to disease progression was 8.4 months, and the median overall survival was 13.6 months (median follow-up of 11.4 months). Neutropenia was the only severe hematologic toxicity (17% of patients), whereas asthenia, nail, ocular and skin disorders were the most common nonhematologic toxicities. Only one death during further follow-up was related to toxicity (caused by pulmonary fibrosis). In conclusion, we found weekly docetaxel to be an active and safe chemotherapy regimen for patients with metastatic breast resistant to previous anthracyclines. This weekly regimen caused minimal myelosupression, while retaining significant activity against advanced breast cancer. Both factors provide attractive possibilities for the development of combination therapies incorporating weekly docetaxel. Nevertheless, the number of patients receiving either dose (40 and 36 mg/m2) which we studied is low and our results require confirmation on larger groups of patients.
Collapse
Affiliation(s)
- M Ramos
- Centro Oncológico de Galicia, A Coruña, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Fírvida J, Amenedo M, Salgado M, Gonzalez-Quintas A, Garcia Mata J, Losada G, Garcia-Gómez J, Calvo M, Rodriguez R. Paclitaxel (T) and carboplatin (C): A phase II study in advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80273-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Llanos M, Tabernero J, Brunet J, Amenedo M, Pallares C, de Andres L, Lopez JJ. CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma. Acta Oncol 1994; 33:935-9. [PMID: 7818928 DOI: 10.3109/02841869409098460] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The results of CHOP treatment in 63 patients with intermediate and high-grade non-Hodgkin's lymphoma (Working Formulation D to I), Ann Arbor stage I to IV were analyzed. The response rate was 87%, 71% complete remission and 16% partial remission with a mean duration of 22 months. The 5-year actuarial survival was 61% (95% confidence interval, 51-70%). The treatment was well tolerated and no deaths due to acute toxicity were observed. Poor prognostic factors in univariate analysis were: high-grade histology, stages III and IV, B symptoms, > or = 4 affected lymph node regions, Karnofsky index < or = 70, erythrocyte sedimentation rate (ESR) > 60 mm, haemoglobin < 100 g/l and elevated lactic dehydrogenase (LDH). Poor prognostic factors in multivariate analysis were: high-grade histology, stages III and IV, haemoglobin < 100 g/l and elevated LDH. In summary, good results were obtained with CHOP chemotherapy, without severe toxicity.
Collapse
Affiliation(s)
- M Llanos
- Department of Oncology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|